In a technical or industrial context, "455" most commonly refers to EN 455, the European standard for single-use medical gloves.
PRED-455 acts as a potent and selective agonist at the 5-HT1A receptor, a subtype of the serotonin receptor. By activating this receptor, PRED-455 increases the release of neurotransmitters, such as dopamine, norepinephrine, and serotonin, which are involved in regulating mood, anxiety, and cognitive function. This mechanism is distinct from that of benzodiazepines, which enhance the activity of GABA, an inhibitory neurotransmitter. As a result, PRED-455 is expected to produce anxiolytic effects without the sedative and dependence liabilities associated with benzodiazepines. PRED-455
Laboratory/Assays: "PRED" is sometimes used as shorthand for the PROGENSA PCA3 Assay, an FDA-approved molecular test used to determine the need for repeat prostate biopsies. In a technical or industrial context, "455" most
Standard Update: A revised version, EN 455-2:2024, was recently released to update testing methods for these physical requirements [26]. 2. Digital Investigations: The "EDP445" Case PRED-455 acts as a potent and selective agonist
PRED-455 was first synthesized in the early 1980s by Shionogi's research team, led by Dr. Kazuo Tatsumi. The team was searching for a novel anxiolytic agent that would overcome the limitations of existing treatments, such as benzodiazepines, which were commonly used at the time. Benzodiazepines, while effective, had significant drawbacks, including dependence, sedation, and cognitive impairment. PRED-455 was designed to target the 5-HT1A receptor, which was known to be involved in regulating anxiety and mood.
Biological Activities
Let me know! 😊